- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Medovex received its first three commercial orders for its DenerveX System.
Medovex (NASDAQ:MDVX) received its first three commercial orders for its DenerveX System.
As quoted in the press release:
The first commercial orders of the DenerveX System included both the DenerveX Kit containing the DenerveX Device and the DenerveX Pro-40 Generators for Germany, UK and Italy.
Manny Sablowski, Sr. Vice President of Sales and Marketing, stated, “We are pleased to have already received three stocking orders from our distributors EDGE Medical of Manchester England, TCB Ortho Division of Germany, and AlfaMed of Porto San Giorgio, Italy. This early interest speaks to the high degree of anticipation of our soon to be performed first human case in the EU.”
Patrick Kullmann, Medovex President and COO, stated, “Receiving multiple orders from three of our distributors so closely on the heels of our recent receipt of CE Mark clearly gives us reason for cautious optimism. We are pleased to be building atop of our recent accomplishment of receiving CE Mark, not just for our shareholders, but for all of those suffering from often debilitating lower back pain associated with Facet Joint Syndrome.”
Click here to read the full press release.
Source: www.marketwired.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.